Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, B- Blockers, Calcium Channel Blockers, Diuretics, Erythropoiesis-stimulating Agents (ESAs), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 12,468.2 million in 2017 and is estimated to exhibit a CAGR of 3.1% over the forecast period (2018-2026).
Availability of increasing number of drugs for diseases such as diabetes including generic as well as branded, rising number of disease awareness initiatives, and ongoing research and development of different therapies are the factors that are expected to fuel growth of the market over the forecast period. For instance, in 2017, Amgen, Inc. received the U.S. Food & Drug Administration (FDA) approval for its Parsabiv (Etelcalcetide), indicated for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease.
Get Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables and Figures) of Chronic Kidney Disease Drugs, https://www.coherentmarketinsights.com/insight/request-pdf/1713
Moreover, in 2017, Cipla launched generic version of Genzyme Corporation’s Renvela tablets in the U.S. In 2017, Aurobindo pharma also launched generic Renvela in the U.S. to control serum phosphorus in chronic kidney disease patients. Furthermore, in January 2018, Mitsubishi Tanabe Pharma Corporation launched Kremezin tablets for chronic renal failure. Similarly, in 2016, OPKO Health, Inc. launched Rayaldee (calcifediol) capsules in the U.S. Dr. Reddy’s Laboratories also launched generic version of Paricalcitol injection for the treatment of chronic kidney disease, in 2016.
Moreover, ongoing research and development for chronic kidney disease medications is expected to boost the market growth over the forecast period. For instance, in January 2018, Cara Therapeutics initiated pivotal phase III trial of Korsuva (CR845/difelikefalin) injection for hemodialysis patients with chronic kidney disease-associated pruritus. Similarly, in 2017, DaVita Clinical Research (DVR), a health care provider-based specialty research organization launched Alliance Site Network for early stage chronic kidney disease trials. This network will provide a clinical research infrastructure to nephrology researchers in the U.S.
Moreover, in 2016, AstraZeneca Plc. initiated two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure. Furthermore, in March 2018, the U.S. Department of Health and Human Services (HHS) entered into a collaboration with American Society of Nephrology to launch Kidney Innovation Accelerator (KidneyX) to accelerate innovation in kidney disease diagnosis and treatment.
Browse 29 Market Data Tables and 47 Figures spread through 178 Pages and in-depth TOC on Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, B- Blockers, Calcium Channel Blockers, Diuretics, Erythropoiesis-Stimulating Agents (ESAs), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026
To know the latest trends and insights prevalent in the chronic kidney disease drugs market Press Release, click the link below: http://bit.ly/34bQsYL
Key Takeaways of the Chronic Kidney Disease Drugs Market:
- The global chronic kidney disease drugs market is expected to exhibit a CAGR of 1% over the forecast period (2018-2026), attributed to increasing number of product launches by generic manufacturers such as Cipla and others
- Ongoing research and development is expected to create lucrative opportunity in the chronic kidney disease drugs market over the forecast period
- Rising number of initiatives to increase awareness about chronic kidney disease, among population is expected to fuel growth of the chronic kidney disease drugs market over the forecast period
- Key players operating in the chronic kidney disease drugs market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc., and Keryx Biopharmaceuticals Inc.
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1713
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027